Why the study?
Does chronic aspirin or NSAID therapy increase the frequency of asymptomatic gastroduodenal lesions compared to no therapy?
Does chronic aspirin or NSAID therapy increase the frequency of asymptomatic gastroduodenal lesions compared to no therapy?
Patients chronically taking aspirin or NSAIDs have a high frequency of asymptomatic gastroduodenal lesions, highlighting the need for awareness of silent gastrointestinal injury.
Answers are grounded in this paper and cite their sources.
Silent lesions common in asymptomatic chronic users; leaves open whether screening or gastroprotection improves outcomes.
Endoscopy in 49 patients without upper gastrointestinal symptoms and who were receiving chronic aspirin or nonsteroidal antiinflammatory drug therapy showed the frequency of gastric and duodenal mucosal lesions to be 76 and 27%, respectively. Fifteen (31%) had gastric ulcers, 31 (63%) had gastric erosions, and 10 (20%) had gastric mucosal hemorrhages. Gastric mucosal lesions were noted in 9 (90%) patients taking plain aspirin, in 25 (74%) receiving nonsteroidal antiinflammatory agents, and in 3 (60%) patients taking enteric-coated aspirin. Duodenal lesions were noted in 30 and 26% of patients taking plain aspirin and nonsteroidal antiinflammatory drugs, respectively. Patients taking enteric-coated aspirin had less severe duodenal injury than patients receiving ibuprofen or indomethacin, but the difference was not statistically significant. Endoscopy in 20 normal subjects not taking aspirin or nonsteroidal antiinflammatory drugs showed no gastroduodenal ulcers, erosions, or hemorrhage. Patients chronically taking antiarthritic drugs, including enteric-coated aspirin, have a high frequency of asymptomatic gastroduodenal lesions.
No takes yet. Share an insight, caveat, or question.
Richard Jaszewski (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: